BioMed Nexus Daily Updates

Your essential biotech, medtech, and pharma recap — no noise, just what matters.

📌 TL;DR

Sana (SANA) showed 14-month islet cell durability at ATTD — no immunosuppression, sustained C-peptide. IND for stem cell version (SC451) expected this year.
Eli Lilly (LLY) escalated the compounding war Thursday, flagging unknown impurity in tirzepatide-B12 combos and requesting FDA recall.
ACIP convenes Wednesday (March 18-19) — first meeting under Kennedy's reconstituted panel; agenda includes "COVID-19 vaccine injuries" but mRNA recommendation push reportedly paused.
NVIDIA GTC kicks off today in San Jose — Lilly's $1B AI factory, BioNeMo expansion, and healthcare AI adoption are the biotech angles to watch.

⚡ Executive Takeaway

The GLP-1 franchise wars are getting personal. Lilly dropped a safety grenade Thursday with data showing compounded tirzepatide-B12 produces an uncharacterized impurity — a move that's part IP protection, part genuine safety concern, and 100% strategic. Meanwhile, Hims/Novo's Monday truce erases a major compounding distribution channel. The compounding model is getting squeezed from both directions: regulatory crackdown and supply normalization.

Elsewhere, Sana's T1D data continues to validate the hypoimmune platform thesis — 14 months of sustained insulin production without immunosuppression is proof-of-concept for a cure paradigm, not a chronic treatment. IND for the scalable stem cell version (SC451) this year sets up 2027 as a pivotal moment.

This week's catalyst density is elevated: GTC for AI/drug discovery signaling, ACIP for vaccine policy risk (30+ states have already decoupled from CDC guidance), and Friday's Rhythm PDUFA for an obesity indication that could be sleeper-significant. 👉 Read Full Analysis

🔮 What To Watch

Wednesday (March 18-19): ACIP meeting at CDC — COVID-19 vaccine injury discussions on agenda. Pending litigation from AAP could still block the meeting. ~30 states have already stopped following ACIP recommendations.
Friday (March 20): Rhythm (RYTM) PDUFA for Imcivree in acquired hypothalamic obesity. Approval would expand TAM into ~5,000 U.S. patients; commercial force already at 42 reps.
Tuesday (March 24): GSK/Alfasigma linerixibat PDUFA for cholestatic pruritus in PBC. First symptom-specific therapy for severe itch in liver disease; $300M upfront deal closed last week pending approval.

🚀 Today's Top Story: Sana's T1D Durability Data Validates Cure Thesis

SANA BIOTECHNOLOGY (SANA) | Friday at ATTD 2026, Seattle
Sana reported 14-month follow-up from its first-in-human study transplanting HIP-modified primary islet cells (UP421) into a single Type 1 diabetes patient — without immunosuppression.
Key findings:
- C-peptide levels at 14 months comparable to months 0-6 — durability confirmed
- Transplanted cells in arm subcutaneous site continued producing insulin
- No safety signals; patient not on immunosuppression throughout
- Glycemic control remained improved vs. baseline
The translation path: UP421 uses donor-derived islets — inherently not scalable. The commercial play is SC451, a stem cell-derived version using the same HIP (hypoimmune) platform technology. Sana expects to file the IND and initiate Phase 1 for SC451 as early as 2026.
Why it matters: This is arguably the most important regenerative medicine proof-of-concept since CRISPR gene editing reached the clinic. A single treatment that restores insulin production without immunosuppression is a cure paradigm, not a maintenance therapy. For context, current islet transplants require lifelong immunosuppression, limiting their utility.
The competitive context: Vertex's VX-880 and VX-264 programs use different immune evasion strategies; Vertex reported strong data but still required immunosuppression in initial cohorts. Sana's approach could be differentiated if it scales.
Catalyst ahead: IND filing for SC451 (2026), Phase 1 initiation.

🏢 Corporate Developments

Eli Lilly (LLY) issued a public safety warning Thursday flagging an uncharacterized impurity formed when compounded tirzepatide is mixed with vitamin B12. The company tested products from compounding pharmacies, medspas, and telehealth platforms and found "significant levels" of the impurity in all 10 samples. Lilly called for FDA to recall all compounded tirzepatide with untested additives. The Alliance for Pharmacy Compounding pushed back, noting lack of shared data.
Hims/Novo Nordisk (HIMS/NVO) — Monday's partnership announcement brought a swift end to the compounding feud. Under the deal, Hims will sell FDA-approved Ozempic and Wegovy (including oral Wegovy) at standard telehealth self-pay prices. Hims immediately stopped advertising compounded GLP-1s. Novo dismissed its patent lawsuit. HIMS +40% on the news; NVO +2%. This effectively exits Hims from the compounding business entirely.
GSK/Alfasigma — GSK licensed global rights to linerixibat to Alfasigma for $300M upfront + $100M on FDA approval + up to $290M in milestones. PDUFA: March 24. First itch-specific therapy for PBC.

🌍 Policy & Public Health

ACIP Meeting (March 18-19) — The reconstituted Advisory Committee on Immunization Practices will convene for the first time since Kennedy replaced all 17 original members. Two new appointees named last week: Drs. Sean Downing and Angelina Farella. Agenda includes discussion of "COVID-19 vaccine injuries" and recommendation methodology.
- Per CNN reporting, administration officials have internally paused a planned push to end mRNA vaccine recommendations due to polling concerns ahead of midterms. However, agenda items remain "subject to change."
- The meeting could still be blocked: AAP's federal lawsuit seeking to halt ACIP activity is pending; Judge Murphy has not yet ruled.
- Practical impact: ~30 states have already decoupled from CDC/ACIP guidance, adopting their own vaccine schedules. The committee's influence has structurally diminished regardless of what happens Wednesday.
FDA Regulatory Updates (Friday March 13):
- Draft guidance on responding to 483 observations — FDA now explicitly requiring root cause analysis documentation
- SUPAC guidance docket opened (comments due June 1, 2026)

📊 Week Recap: March 9-13, 2026

Date	Event	Impact
Monday 3/9	Hims/Novo partnership announced; lawsuit dismissed	HIMS +40%+, NVO +2%
Tuesday 3/10	BioNTech founders announce mRNA spinout plans	BNTX -22%
Wednesday 3/11	BridgeBio FORTIFY Phase 3 data at MDA (LGMD2I); Evotec 800 layoffs; Stryker cyberattack	BBIO filing-ready data
Thursday 3/12	Lilly tirzepatide-B12 impurity warning; Ultragenyx DTX301 Phase 3 hit ammonia endpoint; Capricor HOPE-3 cardiac data	Compounding crackdown escalates
Friday 3/13	Sana 14-month T1D data at ATTD; FDA 483 guidance draft	SANA platform validation

Layoff tracker (week of March 9-13):

Inovio: Roles not supporting INO-3107 eliminated
Vistagen: 20% workforce reduction
Amgen/Horizon: 22 staffers
Evotec: 800 announced
f5 Therapeutics: Shuttered

📅 Week Ahead: March 16-22, 2026

Date	Catalyst	Ticker/Entity	Notes
March 16-19	NVIDIA GTC 2026	NVDA, LLY, RXRX	Lilly AI factory launch; BioNeMo expansion; healthcare AI keynote (Powell) Monday 3pm PT
March 17	Glucotrack at LSI USA '26	GCTK	Implantable CBGM strategy presentation
March 18-19	ACIP Meeting	—	First Kennedy-era meeting; COVID-19 vaccine injury agenda; lawsuit pending
March 20	Rhythm Imcivree PDUFA	RYTM	Acquired hypothalamic obesity sNDA; Phase 3 showed 16.5% BMI reduction
March 24	GSK/Alfasigma linerixibat PDUFA	GSK	Cholestatic pruritus in PBC; Alfasigma controls post-approval
March 26	Novo Nordisk AGM	NVO	Holdings down 34% (-$53B); investor focus on GLP-1 franchise defense
March 28	Rocket Pharma Kresladi PDUFA	RCKT	LAD-I gene therapy

👉 Read Full Analysis

🔒 BioMed Nexus Pro — Institutional Intelligence Brief

In Today's Pro Brief:

🧠 Institutional Read-Through: Sana's platform validation and what it means for the Vertex competitive dynamic
⚖️ Risk Framing: ACIP meeting scenarios — what state-level decoupling means for vaccine manufacturers
📊 Market Positioning: Rhythm PDUFA setup; why the acquired HO indication could be underappreciated
🎯 Catalyst Calendar Deep Dive: GTC healthcare sessions worth tracking; linerixibat approval economics post-Alfasigma deal